Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Study implicates 'arms race' between genes and germs

Biologists have found new evidence of why mice, people and other vertebrate animals carry thousands of varieties of genes to make immune-system proteins named MHCs--even though some of those genes make vertebrate animals susceptible to infections and to autoimmune diseases.

9 Feb 2012

Genzyme announces four-year data from eliglustat tartrate phase 2 trial on Gaucher disease type 1

Genzyme, a Sanofi company, announced today four-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate.

8 Feb 2012

MRI techniques can measure changes in microstructural properties of white matter

Innovative magnetic resonance imaging (MRI) techniques that can measure changes in the microstructure of the white matter likely to affect brain function and the ability of different regions of the brain to communicate are presented in an article in the groundbreaking new neuroscience journal Brain Connectivity, a bimonthly peer-reviewed publication from Mary Ann Liebert, Inc.

8 Feb 2012

Elan fourth quarter total revenue increases 18% to $271.0 million

Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results.

8 Feb 2012

Scientists discover how individual MST neurons function

When you are about to collide into something and manage to swerve away just in the nick of time, what exactly is happening in your brain? A new study from the Montreal Neurological Institute and Hospital - The Neuro, McGill University shows how the brain processes visual information to figure out when something is moving towards you or when you are about to head into a collision.

8 Feb 2012

New scoring method helps predict functional outcomes in stroke

A new scoring method can help doctors quickly decide which stroke patients will respond well to the clot-busting drug alteplase, according to a study published in the February 7, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

7 Feb 2012

Merck Serono enters development agreement with Threshold for hypoxia-targeted drug

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

3 Feb 2012

Immune cells from healthy individuals effectively kill cancer cells

Immune cells from healthy individuals can be the new immune cure for cancer. This treatment can kill cancer cells without destroying neighbouring cells. The hope is to eradicate cancer for ever.

3 Feb 2012

High beta-amyloid levels may affect brain performance in healthy adults

High levels of the protein beta-amyloid in the brain that is associated with Alzheimer's disease may affect brain performance even in healthy adults, according to a study published in the February 1, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

2 Feb 2012

The Methodist Hospital now offers advanced rehabilitation system for treatment of foot drop

The Methodist Hospital Outpatient Rehabilitation Center now offers an advanced rehabilitation system for the treatment of foot drop in people with mobility issues caused by stroke, traumatic brain injury, multiple sclerosis, cerebral palsy and spinal cord injury.

2 Feb 2012

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its full year and fourth quarter 2011 results.

1 Feb 2012

Gilenya prevents and reverses symptoms of ventricular hypertrophy

A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.

30 Jan 2012

Muscle endurance tests can detect abnormalities in early stages of MS

Multiple sclerosis (MS), a neurodegenerative disease, causes periodic attacks of neurologic symptoms such as limb weakness and mobility defects. And while MS patients' walking abilities and muscle strength are examined on a regular basis, doctors have yet to determine when the lower limb muscles begin to deteriorate.

27 Jan 2012

University of Hawaii's ORS to advance employment opportunities for people with disabilities

Kessler Foundation awarded a Signature Employment Grant in the amount of $425,000 to the Office of Research Services at the University of Hawaii, to advance employment opportunities for people with disabilities. The Signature Employment Grant supports the development of a virtual reality (VR) software application, EmployAble: A World Without Barriers, to help jobseekers with disabilities navigate the world of job hunting and adapt to the workplace.

25 Jan 2012

Aphios receives NIH's Phase II SBIR grant to develop APH-0703 for AD

Aphios Corporation has received a Phase II SBIR grant from the National Institutes of Health (NIH) amounting to $2.4 million over two years. The National Institute on Aging (NIA), part of the NIH, awarded the grant to the Aphios Corporation to develop an "Alzheimer's Disease Therapeutic."

24 Jan 2012

FDA approves Genzyme's Fabrazyme manufacturing plant in Framingham

Genzyme, a Sanofi company, announced today that the Food and Drug Administration (FDA) has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme(agalsidase beta). This follows the previously announced approval by the European Medicines Agency (EMA) last week.

24 Jan 2012

Multiple sclerosis drug Gilenya under investigation by FDA and EMA

The US Food and Drugs Administration (FDA) and European Medicines Agency (EMA) are looking at the pros and cons of using Gilenya (fingolimod) in treating the neurological autoimmune disease Multiple Sclerosis (MS).

23 Jan 2012

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease.

21 Jan 2012

FDA approves product label change for Biogen Idec's TYSABRI to treat MS

Today Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis.

21 Jan 2012

Memory retraining using mSMT increases cerebral activation in MS patients

Neuroscientists at Kessler Foundation have documented increased cerebral activation in patients with multiple sclerosis (MS) following memory retraining using the modified Story Memory Technique (mSMT).

18 Jan 2012